⦿ Executive Snapshot

• What: Fennec Pharmaceuticals reports a significant increase in Q1 2026 revenues and announces positive developments for its PEDMARK® product.
• Who: Fennec Pharmaceuticals Inc., CEO Jeff Hackman, University of Arizona Cancer Center.
• Why it matters: The growth in revenue and clinical interest indicates a strengthening market position and potential for broader application of PEDMARK®, which addresses a critical side effect of chemotherapy.

⦿ Key Developments

• Achieved total net revenues of $15.1 million for Q1 2026, a 73% increase compared to $8.8 million in Q1 2025.
• Initiated a third institution-led clinical study evaluating PEDMARK® in adolescents and young adults with head and neck and testicular cancers.
• Four abstracts regarding PEDMARK® will be featured at the 2026 ASCO Annual Meeting, scheduled for May 29 - June 2, 2026.

⦿ Strategic Context

• Fennec Pharmaceuticals is focusing on the therapeutic potential of PEDMARK® to mitigate cisplatin-induced ototoxicity, an issue affecting a significant number of cancer patients undergoing chemotherapy.
• The company's expansion in sales and marketing efforts, alongside positive clinical study results, aligns with industry trends towards enhanced patient care and treatment options in oncology.

⦿ Strategic Implications

• The immediate consequence is an increase in market confidence and adoption of PEDMARK® among healthcare providers, potentially leading to sustained revenue growth.
• Long-term, successful clinical studies and increased utilization of PEDMARK® could establish Fennec as a key player in the oncology market, particularly in addressing treatment-related side effects.

⦿ Risks & Constraints

• Potential risks include regulatory hurdles associated with clinical study approvals and the commercialization process of PEDMARK® in new patient populations.
• Competition from other pharmaceutical companies developing similar therapies or alternative treatments for cisplatin-induced ototoxicity could impact market share.

⦿ Watchlist / Forward Signals

• Key upcoming milestones include the results from the ongoing clinical studies and presentations at the 2026 ASCO Annual Meeting, which could influence investor sentiment and market dynamics.
• Monitoring changes in healthcare provider adoption rates and patient outcomes related to PEDMARK® will be critical in assessing the product's market success.